Dermata Therapeutics, Inc. (DRMA)

0,3370 -0,0190 (-5,34%) Ab 02:52PM EDT. Markt geöffnet.

Dermata Therapeutics, Inc.

3525 Del Mar Heights Road
Suite 332
San Diego, CA 92130
United States
858 800 2543
https://www.dermatarx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 8

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Gerald T. Proehl	Founder, President, CEO & Chairman	392k	N/A	1959
Mr. David F. Hale	Co-Founder & Lead Independent Director	73k	N/A	1949
Ms. Kyri K. Van Hoose CPA, M.B.A.	Senior VP & CFO	415,8k	N/A	1978
Dr. Christopher J. Nardo M.P.H., Ph.D.	Senior VP & Chief Development Officer	443,52k	N/A	1965
Mr. Sean Proehl	Senior Director of Legal & Business Development	N/A	N/A	N/A
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.	Senior Vice President of Regulatory Affairs & Quality Assurance	27,04k	N/A	1951

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Corporate Governance

Dermata Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.